Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Piperacillin + Tazobactam
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Indiana University | Massachusetts General Hospital | Thomas Jefferson University | Washington University School of Medicine | Advocate Illinois Masonic Medical Center | Baptist Memorial Health Care Corporation | Baylor Scott and White Health | Cleveland
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 01, 2017
Lead Product(s) : Piperacillin + Tazobactam
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Indiana University | Massachusetts General Hospital | Thomas Jefferson University | Washington University School of Medicine | Advocate Illinois Masonic Medical Center | Baptist Memorial Health Care Corporation | Baylor Scott and White Health | Cleveland
Deal Size : Inapplicable
Deal Type : Inapplicable